Pamidronate in the treatment of Paget's disease

Bone

Volumn 24, Issue 5 SUPPL. 1, 1999, Pages

  Selby, P L ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; ETIDRONIC ACID; HYDROXYPROLINE; PAMIDRONIC ACID; PARACETAMOL;

BONE PAIN; DRUG SAFETY; FEVER; FLU LIKE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRIDOCYCLITIS; MINERALIZATION; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; PAGET BONE DISEASE; SHORT SURVEY;

EID: 0032904630     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/s8756-3282(99)00060-5     Document Type: Article

References (14)

1. Adami, S., Mian, M., Gatti, P., Rossini, M., Zamberlan, N., Bertoldo, F. et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone 15:415-417; 1994.
2. Adamson, B. B., Gallacher, S. J., Byars, J., Ralston, S. H., Boyle, I. T., and Boyce, B. F. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 342:1459-1460; 1993.
3. Anderson, D. C., Richardson, P. C. Pamidronate and Paget's disease [letter]. Lancet 343:427; 1994.
4. Boyce, B. F., Smith, L., Fogelman, I., Johnston, F., Ralston, S., and Boyle, I. T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet i:821-824; 1984.
5. Can trill, J. A., Buckler, H. M., and Anderson, D. C. Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone. Ann Rheum Dis 45:1012-1018; 1986.
6. Cundy, T., Wattie, D., and King, A. R. High-dose pamidronate in the management of resistant Paget's disease. Calcif Tissue Int 58:6-8; 1996.
7. Fleisch, H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemia and metastatic bone disease. Drugs 42:919-944; 1991.
8. Frijlink, W. B., Bijvoet, O. L., te Velde, J., and Heynen, G. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet i:799-803; 1979.
9. Gibbs, C. J., Aaron, J. E., and Peacock, M. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. Br Med J 292:1227-1229; 1986.
10. Mazieres, B., Ahmed, L, Moulinier, L., Bon, F., Cantagrel, A., and Laroche, M. Pamidronate infusions for the treatment of Paget's disease of bone. Revue Du Rheumatisme (Engl Ed) 63:36-43; 1996.
11. Richardson, P. C., Cantrill, J. A., and Anderson, D. C. Experience of treating 218 patients with Paget's disease of bone using intravenous 3-aminohydroxypropylidene 1-1 bisphosphonate (pamidronate, APD). In: Cohn, D. V., Glorieux, F. H., and Martin, T. J., Eds. Calcium Regulation and Bone Metabolism. New York: Elsevier; 1990; 509-514.
12. Roux, C., Gennari, C., Farrerons, J., Devogelaer, J. P., Mulder, H., Kruse, H. P., Picot, C., Titeux, L., Reginster, J. Y., and Douglas, M. Comparative prospective, double-blind, multicentre study of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 38:851-858; 1990.
13. Smith, R., Russell, R. G., Bishop, M., Woods, C., and Bishop, M. Paget's disease of bone - experience with a diphosphonate in treatment. Q J Med 42:235-256; 1973.
14. Wallace, F., Wong, J., and Reid, I. R. Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. Arch Intern Med 155:1813-1815; 1995.